In vivo study of tetraprenyltoluquinone, an anticancer compounds from Garcinia cowa Roxb

Abstract

Objective: To investigate the in vivo antitumor effect of TPTQ against H-460 lung cancer cell lines in nude mice. Materials and Methods: Female nude mice bearing H-460 tumor at size approximately 5 mm in diameter were treated with a single intraperitoneal dose 800 mg/kg of TPTQ. The vehicletreated (10% tween 80) animals were used as control group. The tumor size and mice body weight were measured for 14 days. Results: Single treatment of 800 mg/kg of TPTQ displayed moderate antitumor activity against H-460 tumor xenografts as compared with vehicle-treated control. The mean time to reach RTV of 4 for vehicle-treated control group was 4.5 days whereas for TPTQ-treated (800 mg/kg) group was 9.5 days. Conclusion:The results showed that TPTQ slowed the tumor growth by 5 days. Thus, TPTQ may be considered as a promising compound in cancer chemotherapy.

Development and validation of TLC-densitometry method for quantification of tetraprenyltoluquinone in the stem bark hexane extract of Garcinia cowa roxb

“…All of the chemicals and reagents used were analytical grade. Reference standard TPTQ was provided from the previous studies [10].…”

“…Two isolated compounds, cowanin and tetraprenyltoluquinone (TPTQ) revealed cytotoxic activity against T47D human breast cancer and H-460, respectively. Furthermore, cowanin could decrease cell mobility and stimulate cell cycle arrest on T47D cancer cells line [7,8,9,10].…”

Tetraprenyltoluquinone Inhibits the Tumor Marker Aldo-Keto Reductase: An in Silico Study

“…Tetraprenyltoluquinone is a compound isolated from the hexane fraction of kandis acid bark (Garcinia cowa, Roxb) [14], which has been reported to have anticancer activity in vivo tested using mice. Administration of tetraprenyltoluquinone compound at a dose of 800 mg/Kg for 14 days in mice with H460 cells implanted subcutaneously in the right pelvis could slow tumor growth within five days of administration of the compound [15].…”

Pharmacokinetic Profile of Tetraprenyltoluquinone After Single-Dose Oral Administration in Male Mice

“…1) reported had a selective cytotoxic activity against small lung cancer [5]. The only in vivo study reported an antitumor activity by inhibiting tumor growth in H-460 tumor xenografted nude mice with dose at 800 mg/kg [6]. This compound also had a strong antiinflammatory activity againts NO [7], immunomodulatory, and safety against RAW 264.7 cell and leukocyte cell [8].…”